Enhance MD vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Enhance MD
Best for lab-monitored compounded GLP-1 with mandatory video visitStarting at $49/mo
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launchStarting at $149/mo
Side-by-Side Comparison
| Feature | Enhance MD | Ro |
|---|---|---|
| Overall Score | ✓8.6/10 | 7.9/10 |
| Starting Price | ✓$49/mo | $149/mo |
| Editorial Rating | ✓4.3 ★ /5 | 4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | ✓39 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Enhance MD
Pros
- ✓Baseline and ongoing metabolic lab panels (CMP, lipids, TSH, HbA1c) at Quest Diagnostics every 6 months — a rigor most compounded GLP-1 providers skip entirely
- ✓Mandatory one-on-one video visit with a US-licensed MD or NP before the first prescription — not a pure-async questionnaire model
- ✓Three pricing tiers including a combined semaglutide + tirzepatide Elite plan ($322/mo ongoing) — useful for patients plateaued on a single GLP-1
- ✓LegitScript-certified 503A pharmacy network: Tru Meds Rx, Strive Pharmacy, Pharmacy Hub
- ✓Aggressive first-month intro pricing: $49 on Core, $99 on Advanced, $189 on Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Not available in 10 states: Alabama, Arkansas, Georgia, Hawaii, Louisiana, Mississippi, Missouri, South Carolina, Tennessee, West Virginia
- ✗Mandatory lab work adds 5–10 days to onboarding vs. async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗First-month intro pricing resets to full tier rate after 30 days — the $49/$99/$189 numbers are not the ongoing cost
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Enhance MD edges out Ro with a higher overall score of 8.6/10 and is particularly strong for lab-monitored compounded GLP-1 with mandatory video visit. Ro remains a solid alternative, especially if you're looking for broadest GLP-1 formulary including Foundayo on day-one of launch.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.